Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study

K Sermet, C Goeminne, S Hantz, A Assaf… - Clinical …, 2023 - Wiley Online Library
Abstract Background Recurrence after Cytomegalovirus (CMV) infection in heart transplant
recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could …

Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation

JB Lerman, CL Green, MR Molina… - Clinical …, 2023 - Wiley Online Library
Introduction Heart transplant (HT) recipients with prior exposure to cytomegalovirus (CMV
R+) are considered intermediate risk for CMV‐related complications. Consensus guidelines …

[HTML][HTML] Could the Cytomegalovirus Viral Load Be Correlated with Cellular Rejection in Asymptomatic Heart Transplant Recipients? A Brief Report

K Mozaffari, N Givtaj, M Hesami… - Research in …, 2024 - journals.lww.com
Materials and Methods: In a cross-sectional study, 90 samples from 65 asymptomatic heart
transplant recipients scheduled for routine endomyocardial biopsy were obtained. All the …

[HTML][HTML] Cytomegalovirus infection in heart transplant recipients: Epidemiology, risk factors, and long-term outcomes from a major transplant center in the United States

BS Bisono-Garcia, ZA Yetmar, V Nair, L Brumble… - JHLT Open, 2024 - Elsevier
Background Despite the use of antiviral prophylaxis, cytomegalovirus (CMV) remains a
common opportunistic infection following heart transplantation. This study analyzes the …

Cytomegalovirus is more than just a simple virus in solid organ transplant recipients

LA Horsfall - Transplant Journal of Australasia, 2023 - search.informit.org
Cytomegalovirus (CMV) is an enveloped double-stranded DNA virus, that in the healthy
population, causes a mild flu-like illness. CMV is the most common, opportunistic viral …